Department of Neurological Surgery, Northwestern University, Chicago, Illinois.
Department of Biochemistry and Molecular Genetics, Northwestern University, Chicago, Illinois.
Clin Cancer Res. 2019 Jan 15;25(2):747-759. doi: 10.1158/1078-0432.CCR-18-1222. Epub 2018 Sep 28.
Gliomas with mutations (IDH1) are less aggressive than IDH1 wild-type (IDH1) gliomas and have global genomic hypermethylation. Yet it is unclear how specific hypermethylation events contribute to the IDH1 phenotype. Previously, we showed that the gene encoding the procoagulant tissue factor (TF), , is among the most hypermethylated and downregulated genes in IDH1 gliomas, correlating with greatly reduced thrombosis in patients with IDH1 glioma. Because TF also increases the aggressiveness of many cancers, the current study explored the contribution of TF suppression to the reduced malignancy of IDH1 gliomas. TF expression was manipulated in patient-derived IDH1 and IDH1 glioma cells, followed by evaluation of and behavior and analyses of cell signaling pathways.
A demethylating agent, decitabine, increased transcription and TF-dependent coagulative activity in IDH1 cells, but not in IDH1 cells. TF induction enhanced the proliferation, invasion, and colony formation of IDH1 cells, and increased the intracranial engraftment of IDH1 GBM164 from 0% to 100% ( = 0.0001). Conversely, TF knockdown doubled the median survival of mice engrafted with IDH1/EGFRvIII GBM6, and caused complete regression of IDH1/EGFR GBM12 ( = 0.001). and effects were linked to activation of receptor tyrosine kinases (RTK) by TF through a Src-dependent intracellular pathway, even when extracellular RTK stimulation was blocked. TF stimulated invasion predominately through upregulation of β-catenin.
These data show that TF suppression is a component of IDH1 glioma behavior, and that it may therefore be an attractive target against IDH1 gliomas.
与 IDH1 野生型(IDH1)胶质瘤相比,携带 突变的神经胶质瘤侵袭性较低,且具有全基因组超甲基化。然而,目前尚不清楚特定的超甲基化事件如何导致 IDH1 表型。先前,我们发现编码促凝血组织因子(TF)的基因 在 IDH1 神经胶质瘤中是最超甲基化和下调的基因之一,这与 IDH1 神经胶质瘤患者的血栓形成大大减少有关。由于 TF 也会增加许多癌症的侵袭性,因此目前的研究探讨了 TF 抑制对降低 IDH1 神经胶质瘤恶性程度的贡献。在源自 IDH1 和 IDH1 神经胶质瘤患者的细胞中操纵 TF 表达,然后评估 和 行为,并分析细胞信号通路。
去甲基化剂地西他滨增加了 IDH1 细胞中的 转录和 TF 依赖性凝血活性,但对 IDH1 细胞没有影响。TF 诱导增强了 IDH1 细胞的增殖、侵袭和集落形成能力,并使 IDH1 GBM164 从颅内植入率为 0%增加到 100%(=0.0001)。相反,TF 敲低使 IDH1/EGFRvIII GBM6 荷瘤小鼠的中位生存期增加了一倍,并导致 IDH1/EGFR GBM12 完全消退(=0.001)。 和 效应与 TF 通过Src 依赖性细胞内途径激活受体酪氨酸激酶(RTK)有关,即使阻断细胞外 RTK 刺激也是如此。TF 刺激侵袭主要是通过上调 β-连环蛋白。
这些数据表明,TF 抑制是 IDH1 神经胶质瘤行为的一个组成部分,因此可能是针对 IDH1 神经胶质瘤的有吸引力的靶点。